Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Stapokibart Phase 3 in Moderate-to-severe Atopic Dermatitis
NCT05265923Phase 3Completed
- Sponsor
- Keymed Biosciences
- Start
- Apr 2022
- Primary completion
- Oct 2023
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in atopic dermatitis (AD) comparing CM310 with Placebo (2 arms). Primary endpoints: Proportion of subjects achieving EASI-75 at 16 weeks and Proportion of subjects achieving IGA 0 or 1 at 16 weeks. Started Apr 2022; status: completed.
02
Drugs
stapokibart
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT05265923.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05265923.